Immune Monitoring Assay for Extracorporeal Photopheresis Treatment Optimization After Heart Transplantation.
dendritic cells
extracorporeal photopheresis
heart transplantation
immune tolerance
regulatory T cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
03
2021
accepted:
23
07
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
25
2
2023
Statut:
epublish
Résumé
Extracorporeal photopheresis (ECP) induces immunological changes that lead to a reduced risk of transplant rejection. The aim of the present study was to determine optimum conditions for ECP treatment by analyzing a variety of tolerance-inducing immune cells to optimize the treatment. Ten ECP treatments were applied to each of 17 heart-transplant patients from month 3 to month 9 post-HTx. Blood samples were taken at baseline, three times during treatment, and four months after the last ECP treatment. The abundance of subsets of tolerance-inducing regulatory T cells (T All BDCA We developed an immune monitoring assay for ECP treatment after heart transplantation by analyzing changes in tolerance-inducing immune cells. This assay allowed differentiation of patients who did and did not show immunological improvement. Based on these results, we propose classification criteria that may allow optimization of the duration of ECP treatment.
Sections du résumé
Background
Extracorporeal photopheresis (ECP) induces immunological changes that lead to a reduced risk of transplant rejection. The aim of the present study was to determine optimum conditions for ECP treatment by analyzing a variety of tolerance-inducing immune cells to optimize the treatment.
Methods
Ten ECP treatments were applied to each of 17 heart-transplant patients from month 3 to month 9 post-HTx. Blood samples were taken at baseline, three times during treatment, and four months after the last ECP treatment. The abundance of subsets of tolerance-inducing regulatory T cells (T
Results
All BDCA
Conclusions
We developed an immune monitoring assay for ECP treatment after heart transplantation by analyzing changes in tolerance-inducing immune cells. This assay allowed differentiation of patients who did and did not show immunological improvement. Based on these results, we propose classification criteria that may allow optimization of the duration of ECP treatment.
Identifiants
pubmed: 34447372
doi: 10.3389/fimmu.2021.676175
pmc: PMC8383491
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
676175Informations de copyright
Copyright © 2021 Dieterlen, Klaeske, Bernhardt, Borger, Klein, Garbade, Lehmann, Ayuk, Reichenspurner and Barten.
Déclaration de conflit d'intérêts
FA declared the following conflict of interest: Therakos: Honoraria, Research funding. MJB declared the following conflict of interest: Therakos: Honoraria. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood. 2005 Mar 1;105(5):2220-6
pubmed: 15546950
J Immunother Cancer. 2013 Jun 27;1:7
pubmed: 25512872
Transplant Rev (Orlando). 2018 Oct;32(4):207-217
pubmed: 29804793
Clin Exp Immunol. 2014 Apr;176(1):120-8
pubmed: 24329680
J Heart Lung Transplant. 2008 Jun;27(6):616-22
pubmed: 18503960
Ther Apher Dial. 2015 Apr;19(2):103-10
pubmed: 25363837
PLoS One. 2015 Dec 22;10(12):e0145763
pubmed: 26693907
J Clin Apher. 2019 Jun;34(3):171-354
pubmed: 31180581
J Exp Med. 2001 Dec 17;194(12):1823-34
pubmed: 11748283
Transplantation. 2007 Jul 15;84(1):31-9
pubmed: 17627234
Transfus Apher Sci. 2012 Apr;46(2):181-8
pubmed: 22115608
Immunotherapy. 2014;6(8):927-44
pubmed: 25313571
PLoS One. 2013;8(4):e61151
pubmed: 23577203
J Exp Med. 2012 Sep 24;209(10):1713-22, S1-19
pubmed: 22966003
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):27-49
pubmed: 32964529
J Clin Apher. 2018 Oct;33(5):591-599
pubmed: 30176056
Clin Exp Immunol. 2011 Aug;165(2):264-77
pubmed: 21635226
Transfusion. 2016 Aug;56(8):2078-84
pubmed: 27250563
Dev Comp Immunol. 2007;31(11):1082-94
pubmed: 17374393
Thromb Haemost. 2020 Jan;120(1):141-155
pubmed: 31887780
Transpl Immunol. 2020 Apr;59:101259
pubmed: 31704267
Transplantation. 2005 Apr 15;79(7):846-50
pubmed: 15818329
J Clin Apher. 2017 Aug;32(4):215-223
pubmed: 27442906
Transplant Proc. 2007 Jan-Feb;39(1):81-3
pubmed: 17275479
Transplantation. 2009 Aug 15;88(3):411-6
pubmed: 19667946
Transplantation. 2007 May 27;83(10):1393-6
pubmed: 17519793
Comput Struct Biotechnol J. 2018 Oct 24;16:435-442
pubmed: 30450167
Transplant Proc. 2007 Jan-Feb;39(1):213-7
pubmed: 17275508
N Engl J Med. 1998 Dec 10;339(24):1744-51
pubmed: 9845709
J Invest Dermatol. 2013 Aug;133(8):2098-100
pubmed: 23519332
Transplantation. 2018 Aug;102(8):1279-1283
pubmed: 29664769
Transfusion. 2013 Sep;53(9):2027-33
pubmed: 23305183
Am J Transplant. 2004 Jan;4(1):65-78
pubmed: 14678036